NCT02825147View on ClinicalTrials.gov

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

July 31, 2017

Conditions
Nasal Type Extranodal NK/T-Cell Lymphoma
Interventions
DRUG

Pegaspargase

DRUG

Methotrexate

DRUG

Dexamethasone

DRUG

Etoposide

RADIATION

radiotherapy

Trial Locations (1)

200025

Shanghai Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT02825147 - Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma | Biotech Hunter | Biotech Hunter